Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs - Archive ouverte HAL Access content directly
Journal Articles Pediatric Nephrology Year : 2021

Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs

(1, 2, 3, 4) , (4, 2, 3) , (5, 2, 6) , (7) , (8) , (2) , (2) , (2, 9) , (2, 9) , (4, 2, 1, 3) , (4, 2, 1, 3) , (2, 1) , (4, 2, 1, 3) , (10) , (11) , (3, 4, 2) , (3, 4, 2) , (2, 9) , (2, 9)
1
2
3
4
5
6
7
8
9
10
11
D. Morin
  • Function : Author
C. Rouges
  • Function : Author

Abstract

INTRODUCTION: In nephropathic cystinosis (NC), adherence to cysteamine remains challenging; poor adherence is worsening the disease progression with a decline of kidney function and increase of extrarenal morbidities. Our objective was to describe adherence to cysteamine in NC patients, using electronic monitoring systems. METHODS: Patients with confirmed NC, aged \textgreater 4 years and receiving oral cysteamine (short acting or delayed release formulation as standard of care) from 3 French reference centers, were included. Adherence to treatment was primarily assessed as the percentage of days with a good adherence score, adherence score rating from 0 (poor) to 2 (good). A descriptive analysis was performed after 1-year follow-up. RESULTS: Seventeen patients (10 girls, median age: 13.9 (5.4-33.0) years) were included. Median age at diagnosis was 17.0 (3.0-76.9) months and age at start of cysteamine was 21.0 (15.5-116.3) months. Median daily dose of cysteamine was 1.05 (0.55-1.63) g/m(2)/day. Over the year, the median percentage of days with a good adherence score was 80 (1-99)% decreasing to 68 (1-99)% in patients \textgreater 11 years old. The median of average number of hours covered by treatment in a day was 22.5 (6.1-23.9) versus 14.9 (9.2-20.5) hours for delayed release versus short acting cysteamine. CONCLUSION: Our data are the first describing a rather good adherence to cysteamine, decreasing in adolescents and adults. We described a potential interest of the delayed release formulation. Our data highlight the need for a multidisciplinary approach including therapeutic education and individualized approaches in NC patients transitioning to adulthood. Graphical abstract.
Not file

Dates and versions

inserm-03282698 , version 1 (09-07-2021)

Identifiers

Cite

S. Gaillard, L. Roche, S. Lemoine, G. Deschênes, D. Morin, et al.. Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs. Pediatric Nephrology, 2021, 36 (3), pp.581-589. ⟨10.1007/s00467-020-04722-0⟩. ⟨inserm-03282698⟩
43 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More